ESSA Pharma Inc. (EPIX)
Oct 9, 2025 - EPIX was delisted (reason: acquired by XenoTherapeutics)
0.195
-0.006 (-3.03%)
Inactive · Last trade price
on Oct 8, 2025
ESSA Pharma Balance Sheet
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | 2019 - 2015 |
| Cash & Equivalents | 85.95 | 103.71 | 33.7 | 57.08 | 137.83 | 56.32 | Upgrade
|
| Short-Term Investments | 23.67 | 23.05 | 114.37 | 110.16 | 57.1 | 22.01 | Upgrade
|
| Cash & Short-Term Investments | 109.62 | 126.76 | 148.08 | 167.24 | 194.93 | 78.33 | Upgrade
|
| Cash Growth | -16.13% | -14.39% | -11.46% | -14.21% | 148.85% | 46.90% | Upgrade
|
| Other Receivables | 0.53 | 0.16 | 0.14 | 0.01 | 0.49 | 0.31 | Upgrade
|
| Receivables | 0.53 | 0.16 | 0.14 | 0.01 | 0.49 | 0.31 | Upgrade
|
| Prepaid Expenses | 0.34 | 0.3 | 0.21 | 1.79 | 1.99 | 1.48 | Upgrade
|
| Other Current Assets | 0.02 | 0.33 | 0.38 | 0.02 | 0.19 | 0.18 | Upgrade
|
| Total Current Assets | 110.5 | 127.56 | 148.8 | 169.06 | 197.6 | 80.3 | Upgrade
|
| Property, Plant & Equipment | - | 0.3 | 0.07 | 0.19 | 0.31 | - | Upgrade
|
| Other Long-Term Assets | - | 0.26 | 0.26 | 0.26 | 0.26 | 0.28 | Upgrade
|
| Total Assets | 110.5 | 128.11 | 149.12 | 169.51 | 198.17 | 80.57 | Upgrade
|
| Accounts Payable | 0.97 | 2.4 | 2.03 | 0.95 | 1.43 | 0.68 | Upgrade
|
| Accrued Expenses | 0.63 | 0.77 | 1.39 | 1.22 | 2.38 | 0.47 | Upgrade
|
| Current Portion of Leases | - | 0.12 | 0.08 | 0.13 | 0.12 | 0.06 | Upgrade
|
| Total Current Liabilities | 1.6 | 3.3 | 3.5 | 2.31 | 3.93 | 1.2 | Upgrade
|
| Long-Term Leases | - | 0.21 | - | 0.08 | 0.21 | - | Upgrade
|
| Other Long-Term Liabilities | - | - | - | - | 0.02 | 0.13 | Upgrade
|
| Total Liabilities | 1.6 | 3.51 | 3.5 | 2.39 | 4.16 | 1.33 | Upgrade
|
| Common Stock | 279.86 | 279.86 | 278.16 | 278.09 | 277.42 | 131.09 | Upgrade
|
| Additional Paid-In Capital | 58.05 | 54.81 | 49.05 | 44.04 | 36.44 | 31.2 | Upgrade
|
| Retained Earnings | -226.91 | -208 | -179.46 | -152.88 | -117.78 | -80.97 | Upgrade
|
| Comprehensive Income & Other | -2.1 | -2.06 | -2.12 | -2.14 | -2.08 | -2.08 | Upgrade
|
| Total Common Equity | 108.9 | 124.61 | 145.63 | 167.12 | 194.01 | 79.24 | Upgrade
|
| Shareholders' Equity | 108.9 | 124.61 | 145.63 | 167.12 | 194.01 | 79.24 | Upgrade
|
| Total Liabilities & Equity | 110.5 | 128.11 | 149.12 | 169.51 | 198.17 | 80.57 | Upgrade
|
| Total Debt | - | 0.33 | 0.08 | 0.21 | 0.33 | 0.06 | Upgrade
|
| Net Cash (Debt) | 109.62 | 126.43 | 148 | 167.03 | 194.6 | 78.27 | Upgrade
|
| Net Cash Growth | -15.90% | -14.57% | -11.39% | -14.17% | 148.61% | 57.77% | Upgrade
|
| Net Cash Per Share | 2.47 | 2.86 | 3.36 | 3.79 | 5.06 | 3.49 | Upgrade
|
| Filing Date Shares Outstanding | 47.31 | 44.39 | 44.14 | 44.07 | 43.98 | 33.6 | Upgrade
|
| Total Common Shares Outstanding | 44.39 | 44.39 | 44.1 | 44.07 | 43.98 | 32.06 | Upgrade
|
| Working Capital | 108.9 | 124.26 | 145.3 | 166.75 | 193.67 | 79.09 | Upgrade
|
| Book Value Per Share | 2.45 | 2.81 | 3.30 | 3.79 | 4.41 | 2.47 | Upgrade
|
| Tangible Book Value | 108.9 | 124.61 | 145.63 | 167.12 | 194.01 | 79.24 | Upgrade
|
| Tangible Book Value Per Share | 2.45 | 2.81 | 3.30 | 3.79 | 4.41 | 2.47 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.